Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model - Chen, H-W; Chang, Y-F; Chuang, H-Y; Tai, W-T; Hwang, J-J (Prostate cancer and prostatic diseases, 2012)
Keywords: 631/67/1059/602; 631/67/589/466; 631/92/436/2388; Animal models; Animals; Anticancer properties; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Apoptosis; Biomedical and Life Sciences; Biomedicine; Cancer cells; Cancer Research; Carcinoma - diagnosis; Carcinoma - drug therapy; Carcinoma - metabolism; Cell cycle; Cell Line, Tumor; Cell Proliferation - drug effects; Cell survival; Disease Models, Animal; Drug therapy; Enzyme inhibitors; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - therapeutic use; Fatty Acid Synthases - antagonists & inhibitors; Fatty acids; Fatty-acid synthase; G1 Phase Cell Cycle Checkpoints - drug effects; Growth inhibition; Health aspects; Herpes simplex; Humans; In vivo methods and tests; Kinases; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Imaging; Molecular Targeted Therapy; original-article; Physiological aspects; Prostate cancer; Prostate carcinoma; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; siRNA; Thymidine; Thymidine kinase; Tumors; Taiwan; C75; siFASN; molecular imaging; fatty acid synthase